A Phase 1 interventional study of Nivolumab in Severe Sepsis, sponsored by Bristol-Myers Squibb. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-23.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 517 studies in Sepsis with a site in United States — 75 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.
Among the 517 studies in Sepsis with a site in United States, this one is the 209th largest by enrollment of the 310 interventional ones that give a count, is one of 23 that started in 2016, is one of 32 in phase 1, and was the 256th registered.
2,421 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →75 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:
Deepull Diagnostics S.L. · Sites in United States, France, Germany and 2 more countries
Intermountain Health Care, Inc. · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 0 days–7 days
Vanderbilt University Medical Center · Sites in United States
Ages 1 days–12 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 321 Sepsis studies recruiting now, 213 (66%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
517 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 80 · Phase 3 47 · Phase 4 25
First in 1988; this study’s year is marked. 23 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 102 across 1,167 interventional studies indexed under Sepsis.
Median enrollment 84 across the 310 interventional studies, 183 across the 204 observational. Of the 361 that completed or were terminated, 117 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
135 of 517 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 5 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
37 of the studies in Sepsis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06817408Mayo ClinicDynamics of Organ Damage and Immune Exhaustion During Sepsis | 2026-12 |
| NCT04796285Brigham and Women's HospitalA Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor | 2026-12 |
| NCT01315782The University of Texas Health Science Center, HoustonAlveolar Dead Space as Predictor of Organ Failure in Severe Sepsis | 2026-12 |
| NCT06692400Loma Linda UniversityThe Effects of Endotracheal Suctioning on Pain and Serum Markers | 2026-12 |
| NCT03133208University of FloridaSepsis Associated Encephalopathy (SAE) Biomarkers | 2026-12-15 |
Add all 37 to your calendar (.ics) → With an account.
Among the 517 studies in Sepsis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 1
Biological: Nivolumab
Dose 2
Biological: Nivolumab
Specified dose on specified days
Also known as: BMS-936558
Percentage of Incidence Rates of Serious Adverse Events (SAEs), Adverse Events (AEs), Immune-mediated AEs, AEs Leading to Discontinuation, and Deaths
Time frame: Screening, day -1, day 1 and subsequent days after, up to 90 days
Composite of Vital Signs and Electrocardiogram (ECG)
Includes body temperature, respiratory rate, blood pressure and heart rate. Blood pressure and heart rate should be measured after the participant has been resting quietly for at least 5 minutes.
Time frame: Screening up to 90 days (Discharge)
Peak Nivolumab Serum Concentration (Cmax)
Participants peak nivolumab serum concentration
Time frame: Day 1 and subsequent days after, up to 90 days
Trough Nivolumab Serum Concentration (Cmin)
Participant trough nivolumab serum concentration
Time frame: Day 1 and subsequent days after, up to 90 days
Average Nivolumab Serum Concentration (Cavg)
Participant average nivolumab serum concentration
Time frame: Day 1 and subsequent days after, up to 90 days
Time of Maximum Observed Concentration (Tmax)
Participant observed time of maximum concentration
Time frame: Day 1 and subsequent days after, up to 90 days
Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration [AUC(0-T)]
Area under the serum concentration-time curve from time zero to time of last quantifiable concentration
Time frame: Day 1 and subsequent days after, up to 90 days
Total Clearance (CLT)
Total clearance of serum concentration of nivolumab
Time frame: Day 1 and subsequent days after, up to 90 days
Volume of Distribution (Vd)
Vlume of distribution of nivolumab serum concentration
Time frame: Day 1 and subsequent days after, up to 90 days
Half-life (T1/2)
Half-Life of nivolumab derived from serum concentration
Time frame: Day 1 and subsequent days after, up to 90 days
Receptor Occupancy
Receptor occupancy on T cells at baseline and after study treatment administration at planned sampling time points
Time frame: Day 1 and up to day 90 (discharge)
Number of Participants With Detectable Anti-nivolumab Antibodies
Participant with positive anti-drug antibody detection
Time frame: Baseline and subsequent days after, up to 90 days
Number of Participants With Any Detectable Anti-drug Antibodies
Time frame: Baseline and subsequent days after, up to 90 days
| Milestone | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Started | 15 | 16 |
| Completed | 8 | 7 |
| Not completed | 7 | 9 |
| Withdrew: Not disclosed | 2 | 2 |
| Withdrew: Subject no longer meets study criteria | 1 | 0 |
| Withdrew: Subject withdrew consent | 0 | 1 |
| Withdrew: Death | 4 | 6 |
| Percentage | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Serious Adverse Events (SAEs) | 6.7 | 43.8 |
| Adverse Events (AEs) | 93.3 | 87.5 |
| Immune-Mediated Adverse Events | 53.3 | 81.3 |
| AEs leading to discontinuation | 0.0 | 0.0 |
| Deaths | 40.0 | 38.7 |
Includes body temperature, respiratory rate, blood pressure and heart rate. Blood pressure and heart rate should be measured after the participant has been resting quietly for at least 5 minutes.
| Percentage | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| ECG Change from Baseline (Discharge) | -18.0 ± 31.68 | -29.0 ± 3.46 |
| Vital Signs - Diastolic Pressure (mmHg) Screening | 61.5 ± 20.37 | 58.5 ± 9.00 |
| Vital Signs - Systolic Pressure (mmHg) Screening | 116.5 ± 21.48 | 105.5 ± 14.65 |
| Vital Signs - Heart Rate (beats/min) Screening | 80.1 ± 21.34 | 94.6 ± 16.64 |
| Vital Signs - Resp. Rate (breaths/min) Screening | 23.0 ± 6.08 | 24.4 ± 8.83 |
| Vital Signs - Temperature (C) Screening | 37.19 ± 0.79 | 37.11 ± 0.77 |
| Vital Signs - Diastolic Pressure (mmHg) Discharge | 79.7 ± 16.49 | 70.5 ± 16.28 |
| Vital Signs - Systolic Pressure (mmHg) Discharge | 129.0 ± 25.06 | 110.0 ± 16.47 |
| Vital Signs - Heart Rate (beats/min) Discharge | 85.3 ± 18.89 | 86.5 ± 19.76 |
| Vital Signs - Resp. Rate (breaths/min) Discharge | 18.8 ± 2.71 | 17.5 ± 3.32 |
| Vital Signs - Temperature (C) Discharge | 36.60 ± 0.276 | 36.90 ± 0.337 |
Participants peak nivolumab serum concentration
| ug/mL | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Peak Nivolumab Serum Concentration (Cmax) | 123 ± 85.4 | 246 ± 85.4 |
Participant trough nivolumab serum concentration
| ug/mL | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Trough Nivolumab Serum Concentration (Cmin) | 21.6 ± 39 | 43.2 ± 39 |
Participant average nivolumab serum concentration
| ug/mL | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Average Nivolumab Serum Concentration (Cavg) | 42.7 ± 28.5 | 85.4 ± 28.5 |
Participant observed time of maximum concentration
| hours | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Time of Maximum Observed Concentration (Tmax) | 1.67 (1.47 to 24.3) | 1.53 (1.37 to 48.0) |
Area under the serum concentration-time curve from time zero to time of last quantifiable concentration
| h*ug/mL | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration [AUC(0-T)] | 18099 ± 51 | 32130 ± 83 |
Total clearance of serum concentration of nivolumab
| L/h | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Total Clearance (CLT) | 0.025 ± 50 | 0.027 ± 85 |
Vlume of distribution of nivolumab serum concentration
| L | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Volume of Distribution (Vd) | 12.0 ± 42 | 13.3 ± 54 |
Half-Life of nivolumab derived from serum concentration
| hours | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Half-life (T1/2) | 353 ± 126.5 | 378 ± 189.6 |
Receptor occupancy on T cells at baseline and after study treatment administration at planned sampling time points
| Percentage | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Study Discharge | 81.272 ± 27.69 | 71.14 ± 34.83 |
Participant with positive anti-drug antibody detection
| Percentage | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Number of Participants With Detectable Anti-nivolumab Antibodies | 73.3 | 75.0 |
| Percentage | Nivolumab (480 mg) | Nivolumab (960 mg) |
|---|---|---|
| Number of Participants With Any Detectable Anti-drug Antibodies | 26.7 | 56.3 |
Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from Day 1 following single dose of nivolumab, up until Day 90.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NIVOLUMAB 480mg | 4/15 (26.7%) | 1/15 (6.7%) | 14/15 (93.3%) |
| NIVOLUMAB 960mg | 6/16 (37.5%) | 7/16 (43.8%) | 14/16 (87.5%) |
| Event | NIVOLUMAB 480mg | NIVOLUMAB 960mg |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/15 | 2/16 |
| Intra-abdominal haemorrhageGastrointestinal disorders | 1/15 | 0/16 |
| Abdominal abscessInfections and infestations | 1/15 | 0/16 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 0/15 | 1/16 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/15 | 1/16 |
| Cardiac arrestCardiac disorders | 0/15 | 1/16 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/15 | 1/16 |
| MegacolonGastrointestinal disorders | 0/15 | 1/16 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/15 | 1/16 |
| UrosepsisInfections and infestations | 0/15 | 1/16 |
| Event | NIVOLUMAB 480mg | NIVOLUMAB 960mg |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 6/15 | 8/16 |
| HypotensionVascular disorders | 6/15 | 4/16 |
| PyrexiaGeneral disorders | 5/15 | 6/16 |
| DiarrhoeaGastrointestinal disorders | 5/15 | 2/16 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/15 | 5/16 |
| NauseaGastrointestinal disorders | 4/15 | 2/16 |
| LeukocytosisBlood and lymphatic system disorders | 2/15 | 4/16 |
| HypernatraemiaMetabolism and nutrition disorders | 3/15 | 4/16 |
| MalnutritionMetabolism and nutrition disorders | 1/15 | 4/16 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 0/15 | 4/16 |
| Age, Continuous(Years) | Nivolumab (480 mg) | Nivolumab (960 mg) | Total |
|---|---|---|---|
| Mean | 56.6 ± 12.30 | 58.4 ± 15.16 | 57.5 ± 13.65 |
| Sex: Female, Male(Participants) | Nivolumab (480 mg) | Nivolumab (960 mg) | Total |
|---|---|---|---|
| Female | 4 | 6 | 10 |
| Male | 11 | 10 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab (480 mg) | Nivolumab (960 mg) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 13 | 15 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Nivolumab (480 mg) | Nivolumab (960 mg) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 6 |
| White | 12 | 11 | 23 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Jan 2018, 12 months.
Results were first posted in Apr 2019, 1 year 2 months after primary completion.
Of 33 phase 1 interventional studies under Sepsis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's 12 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab